{
    "data": [
        {
            "id": "6903c454ecb8a7000145c077",
            "title": "Behind the Scenes of Docusign&#39;s Latest Options Trends",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Deep-pocketed investors have adopted a bullish approach towards Docusign (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/DOCU\" target=\"_blank\">DOCU</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DOCU usually suggests something big is about to happen.</p><!--/$--><!--$--><p class=\"block core-block\">We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Docusign. This level of activity is out of the ordinary.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The general mood among these heavyweight investors is divided, with 62% leaning bullish and 25% bearish. Among these notable options, 2 are puts, totaling $63,713, and 6 are calls, amounting to $264,490.</p><!--/$--><!--$--><h3 class=\"block core-block\">Predicted Price Range</h3><!--/$--><!--$--><p class=\"block core-block\">Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $85.0 for Docusign over the recent three months. </p><!--/$--><!--$--><div class=\"sc-ewfYpr ctXQJP\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Volume &amp; Open Interest Trends</h3><!--/$--><!--$--><p class=\"block core-block\">In today's trading context, the average open interest for options of Docusign stands at 725.25, with a total volume reaching 1,006.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Docusign, situated within the strike price corridor from $70.0 to $85.0, throughout the last 30 days.</p><!--/$--><!--$--><h3 class=\"block core-block\">Docusign Option Volume And Open Interest Over Last 30 Days</h3><!--/$--><!--$--><div class=\"sc-feVKPA LhjAx core-image flex items-center justify-center\"><span style=\"background:none;border:0;box-sizing:border-box;display:inline-block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:relative;max-width:100%\"><span style=\"background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;padding:0;width:initial;max-width:100%\"><img alt=\"\" aria-hidden=\"true\" src=\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMTUwMCIgaGVpZ2h0PSI4MDAiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyIgdmVyc2lvbj0iMS4xIi8+\" style=\"background:none;border:0;display:block;height:initial;margin:0;max-width:100%;opacity:1;padding:0;width:initial\"/></span><img alt=\"\" decoding=\"async\" loading=\"lazy\" src=\"data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/><noscript><img alt=\"\" decoding=\"async\" fetchpriority=\"low\" loading=\"lazy\" sizes=\"(max-width: 800px) 1500px, (min-width: 800px) 1500px\" src=\"https://www.benzinga.com/files/images/story/2025/1761854549_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=3840\" srcset=\"https://www.benzinga.com/files/images/story/2025/1761854549_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920 1x, https://www.benzinga.com/files/images/story/2025/1761854549_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=3840 2x\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/></noscript></span></div><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Largest Options Trades Observed:</h3><!--/$--><!--$--><!--/$--><!--$--><h3 class=\"block core-block\">About Docusign</h3><!--/$--><!--$--><p class=\"block core-block\">Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Having examined the options trading patterns of Docusign, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p><!--/$--><!--$--><h3 class=\"block core-block\">Docusign's Current Market Status</h3><!--/$--><!--$--><ul class=\"block core-block\">\n<li>Trading volume stands at 3,876,848, with DOCU's price up by 3.83%, positioned at $71.62.</li>\n<li>RSI indicators show the stock to be may be approaching overbought.</li>\n<li>Earnings announcement expected in 35 days.</li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">What The Experts Say On Docusign</h3><!--/$--><!--$--><p class=\"block core-block\">A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $124.0.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Turn $1000 into $1270 in just 20 days?</strong></p><!--/$--><!--$--><p class=\"block core-block\">20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href=\"https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage\" target=\"_blank\"><strong>Click here for access</strong></a>.\n* In a cautious move, an analyst from JMP Securities downgraded its rating to Market Outperform, setting a price target of $124. </p><!--/$--><!--$--><p class=\"block core-block\">Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Docusign options trades with real-time alerts from <a href=\"https://www.benzinga.com/pro/\" target=\"_blank\">Benzinga Pro</a>.</p><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/options/25/10/48543200/behind-the-scenes-of-docusigns-latest-options-trends",
            "pub_date": "2025-10-31 04:02:32",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903c4d8ecb8a7000145c132",
            "title": "Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here&#39;s How ETFs Stand To Gain",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><a href=\"https://www.benzinga.com/etfs\" target=\"_blank\">Healthcare ETFs</a> are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As <strong>Eli Lilly And Co</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/LLY\" target=\"_blank\">LLY</a>), <strong>Novo Nordisk A/S</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NVO\" target=\"_blank\">NVO</a>), and <strong>Pfizer Inc</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/PFE\" target=\"_blank\">PFE</a>) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far less calorie-dense ways to play the trend.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><em>Elli Lily stock is up almost 5% on Thursday. <a href=\"https://www.benzinga.com/quote/LLY\" target=\"_blank\">Track its prices, live</a>.</em></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The <strong>Health Care Select Sector SPDR Fund</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/XLV\" target=\"_blank\">XLV</a>) is one of the largest and most liquid U.S. healthcare ETFs, with Eli Lilly as its top holding. Lilly alone constitutes over 12% of the fund, which also includes heavyweights like <strong>Johnson &amp; Johnson </strong>(NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/JNJ\" target=\"_blank\">JNJ</a>), <strong>AbbVie Inc</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/ABBV\" target=\"_blank\">ABBV</a>) and <strong>Merck &amp; Co Inc</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/MRK\" target=\"_blank\">MRK</a>), making XLV a go-to for investors seeking broad yet concentrated exposure to the pharma surge.</p><!--/$--><!--$--><p class=\"block core-block\">The <strong>iShares U.S. Pharmaceuticals ETF</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/IHE\" target=\"_blank\">IHE</a>) offers an even more targeted play, with roughly 20 of America's biggest drugmakers, including Lilly and Pfizer. The fund has gained traction this week as investors digest Lilly's blowout earnings and Novo's <a href=\"https://www.benzinga.com/m-a/25/10/48533502/pfizer-blasts-novo-nordisks-9-billion-counteroffer-for-metsera-as-reckless\" target=\"_blank\">audacious takeover bid for Metsera</a>. On Thursday, the fund was up almost 2%. </p><!--/$--><!--$--><p class=\"block core-block\">The <strong>VanEck Pharmaceutical ETF</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/PPH\" target=\"_blank\">PPH</a>) adds a global flavor to the mix, combining U.S. and European pharma names like Novo Nordisk alongside Lilly and Pfizer to give it a front-row seat to the obesity drug arms race.</p><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><p class=\"block core-block\">For investors who prefer the theme-first approach, the <strong>Roundhill GLP-1 &amp; Weight Loss ETF </strong>(NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/OZEM\" target=\"_blank\">OZEM</a>) has emerged as a pure-play bet on the anti-obesity revolution. The fund focuses exclusively on companies leading the charge of this megatrend in weight loss and diabetes treatment, from established GLP-1 producers to emerging biotech developers.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Eli Lilly Leads, Rivals Fight </h2><!--/$--><!--$--><p class=\"block core-block\">Setting the tone for the sector were third-quarter results from Eli Lilly, whose adjusted earnings of $7.02 per share topped estimates and raised its full-year profit forecast to as high as $23.70. </p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">But across the Atlantic, Novo Nordisk is making headlines of its own, launching a $6.5 billion counterbid for U.S. biotech Metsera, edging out Pfizer’s earlier deal. Metsera is developing a few experimental weight-loss treatments, including a shot that can be taken less frequently than Novo Nordisk's Wegov, making the deal attractive to the giant.</p><!--/$--><!--$--><p class=\"block core-block\">Pfizer, which is still regaining its footing after the pandemic vaccine windfall faded, called Novo’s move “reckless” and anticompetitive, but the fight underscores how high the stakes have become in the GLP-1 gold rush.</p><!--/$--><!--$--><p class=\"block core-block\">With Lilly tightening its lead, Novo flexing its balance sheet, and Pfizer trying to claw back relevance, the obesity-drug race is reshaping the global pharma landscape-and ETFs are emerging as the easiest way to stay invested in the frenzy. </p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48543376\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/etfs/sector-etfs/25/10/48535168/nvidias-5-trillion-milestone-turns-these-ai-etfs-into-hot-trades\" target=\"_blank\">Nvidia’s $5 Trillion Milestone Turns These AI ETFs Into Hot Trades</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by shisu_ka via Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg",
            "link": "https://www.benzinga.com/etfs/sector-etfs/25/10/48543376/eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash-heres-how-etfs-stand-to-gain",
            "pub_date": "2025-10-31 04:04:44",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903ce7becb8a7000145cacb",
            "title": "Here&#39;s How Much $1000 Invested In RBC Bearings 10 Years Ago Would Be Worth Today",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">RBC Bearings (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/RBC\" target=\"_blank\">RBC</a>) has outperformed the market over the past 10 years by 6.92% on an annualized basis producing an average annual return of 19.37%. Currently, RBC Bearings has a market capitalization of $12.83 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $1000 In RBC:</strong> If an investor had bought $1000 of RBC stock 10 years ago, it would be worth <strong>$5,849.88</strong> today based on a price of $406.45 for RBC at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">RBC Bearings's Performance Over Last 10 Years</h3><!--/$--><!--$--><div class=\"sc-feVKPA LhjAx core-image flex items-center justify-center\"><span style=\"background:none;border:0;box-sizing:border-box;display:inline-block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:relative;max-width:100%\"><span style=\"background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;padding:0;width:initial;max-width:100%\"><img alt=\"\" aria-hidden=\"true\" src=\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMTUwMCIgaGVpZ2h0PSI4MDAiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyIgdmVyc2lvbj0iMS4xIi8+\" style=\"background:none;border:0;display:block;height:initial;margin:0;max-width:100%;opacity:1;padding:0;width:initial\"/></span><img alt=\"\" decoding=\"async\" loading=\"lazy\" src=\"data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/><noscript><img alt=\"\" decoding=\"async\" fetchpriority=\"low\" loading=\"lazy\" sizes=\"(max-width: 800px) 1500px, (min-width: 800px) 1500px\" src=\"https://www.benzinga.com/files/images/story/2025/1761857148_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=3840\" srcset=\"https://www.benzinga.com/files/images/story/2025/1761857148_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920 1x, https://www.benzinga.com/files/images/story/2025/1761857148_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=3840 2x\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/></noscript></span></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-ewfYpr ctXQJP\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/25/10/48545547/heres-how-much-1000-invested-in-rbc-bearings-10-years-ago-would-be-worth-today",
            "pub_date": "2025-10-31 04:45:51",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903cd42ecb8a7000145c9c7",
            "title": "Roku Q3 Earnings Highlights: Double Beat, Positive Operating Income For First Time Since 2021",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Streaming company <strong>Roku Inc</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/ROKU\" target=\"_blank\">ROKU</a>) reported third-quarter financial results Thursday<a href=\"https://www.benzinga.com/earnings\" target=\"_blank\"> after market close.</a></p><!--/$--><!--$--><p class=\"block core-block\">Here are the key highlights.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>What Happened: </strong>Roku reported third-quarter net revenue of $1.211 billion, up 14% year-over-year. The revenue total beat a Street consensus estimate of $1.206 billon, according to data<a href=\"https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent103025&amp;t=be2bearmibe3na1\" target=\"_blank\"> from Benzinga Pro.</a></p><!--/$--><!--$--><p class=\"block core-block\">The company reported third-quarter platform revenue of $1.06 billion, up 17% year-over-year and devices revenue of $146.0 million, down 5% year-over-year.</p><!--/$--><!--$--><p class=\"block core-block\">Roku said platform revenue was boosted by strong streaming services distribution and video advertising activities.</p><!--/$--><!--$--><p class=\"block core-block\">Third-quarter earnings per share were 16 cents per share, beating a Street consensus estimate of 9 cents per share.</p><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><p class=\"block core-block\">\"We delivered strong Q3 results, achieving positive operating income ahead of schedule and for the first time since 2021,\" the company said.</p><!--/$--><!--$--><p class=\"block core-block\">Streaming hours for the company were 36.5 billion in the quarter, up 4.5 billion hours year-over-year. The Roku Channel was the number two app on the platform for engagement in the United States.</p><!--/$--><!--$--><p class=\"block core-block\">The company said video advertising on Roku grew faster year-over-year than the overall digital advertising market in the United States.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Read Also: <a href=\"https://www.benzinga.com/markets/tech/25/09/47698105/roku-enters-portable-entertainment-market-with-smart-projector\" target=\"_blank\">Roku Enters Portable Entertainment Market With Smart Projector</a></strong></p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>What's Next: </strong>Roku expects fourth quarter net revenue to be $1.35 billion, up 12% year-over-year. The company expects fourth-quarter platform revenue to be up 15% year-over-year and devices revenue to be in line year-over-year.</p><!--/$--><!--$--><p class=\"block core-block\">The company raised its full-year platform revenue estimate to $4.11 billion, up 17% year-over-year.</p><!--/$--><!--$--><p class=\"block core-block\">Roku also raised its full-year Adjusted EBITDA forecast to $395 million.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">\"We remain confident in our strategy and our long-term growth. We see significant opportunity to drive double-digit growth in Platform revenue in 2026 and beyond while increasing profitability,\" the company said.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>ROKU Price Action</strong>: Roku stock is down 7.5% to $92.56 in after-hours trading Thursday versus a 52-week trading range of $52.43 to $107.25.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48545304\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/trading-ideas/long-ideas/25/08/47131632/cathie-woods-top-10-stock-picks-unpacking-ark-funds-innovation-picks-for-the-next-decade\" target=\"_blank\">Cathie Wood’s Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Image created using artificial intelligence via Midjourney.</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/roku-mid2.png",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48545304/roku-q3-earnings-highlights-double-beat-positive-operating-income-for-first-time-since-2021",
            "pub_date": "2025-10-31 04:40:38",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6903cc88ecb8a7000145c948",
            "title": "Coinbase Stock Climbs After Q3 Earnings: Here&#39;s Why",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Coinbase Global Inc. </strong>(NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/COIN\" target=\"_blank\">COIN</a>) shares climbed after the company released its third-quarter earnings report after Thursday's closing bell, beating expectations on the top<a href=\"https://www.benzinga.com/pressreleases/25/10/b48543867/coinbase-releases-third-quarter-2025-shareholder-letter\" target=\"_blank\"> and bottom lines. </a></p><!--/$--><!--$--><p class=\"block core-block\">Here’s a look at the key details from the report. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>COIN stock is moving. <a href=\"https://www.benzinga.com/quote/COIN\" target=\"_blank\">See the real-time price action here.</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><strong>The Details:</strong> Coinbase Global reported quarterly earnings of $1.44 per share, which beat the analyst estimate of $1.11 by 29.38%.</p><!--/$--><!--$--><p class=\"block core-block\">Quarterly revenue came in at $1.86 billion, which beat the analyst consensus estimate of $1.79 billion and was up from revenue of $1.2 billion from the same period last year.</p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\"><strong>Coinbase reported the following third quarter highlights:</strong></p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>Transaction revenue was $1 billion, up 37% Q/Q. </li>\n<li>Subscription and services revenue was $747 million, up 14% Q/Q. </li>\n<li>Total operating expenses declined $134 million or 9% Q/Q to $1.4 billion.</li>\n<li>Full-time employees increased 12% Q/Q to 4,795. </li>\n<li>Net income was $433 million, Adjusted Net Income was $421 million, and Adjusted EBITDA was $801 million.</li>\n</ul><!--/$--><!--$--><div class=\"sc-eQzVdq kfhAgV\"></div><!--/$--><!--$--><p class=\"block core-block\">“Q3 was a strong quarter for Coinbase. We drove solid financial results, maintained focus on shipping innovative products, and continued building the foundation of the Everything Exchange,” Coinbase CEO <strong>Brian Armstrong</strong> said in <a href=\"https://investor.coinbase.com/files/doc_financials/2025/q3/Q3-25-Shareholder-Letter.pdf\" target=\"_blank\">a letter </a>to shareholders. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Outlook: </strong>Coinbase expects October transaction revenue to be approximately $385 million. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>COIN Stock Price:</strong> According to data from<a href=\"https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw\" target=\"_blank\"> Benzinga Pro</a>, Coinbase stock was up 0.45% at $333.56 in Thursday's extended trading. </p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48545193\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><a href=\"https://www.benzinga.com/analyst-stock-ratings/price-target/25/10/48535521/googles-q3-sends-stock-to-new-highs-analysts-say-ai-momentum-is-nanobananas\" target=\"_blank\"><strong>Google’s Q3 Sends Stock To New Highs, Analysts Say ‘AI Momentum Is Nanobananas’</strong></a></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/Germany---April-19-2024-Coinbase-Mobile-.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48545193/coinbase-stock-climbs-after-q3-earnings-heres-why",
            "pub_date": "2025-10-31 04:37:32",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}